PNC-27 Peptide Selectively Kills Cancer Cells by Disrupting Membranes and Targeting HDM-2

Cancer remains a leading cause of death, often due to uncontrolled cell proliferation and resistance to conventional therapies. The p53 tumor suppressor protein is crucial for preventing cancer, but its function is frequently compromised, often by overexpression of HDM-2 (also known as MDM2), which degrades p53. Current treatments struggle with specificity, leading to off-target effects; this study investigates a novel peptide's ability to selectively target cancer cells by interfering with HDM-2 and inducing membrane disruption.

PNC-27 demonstrated potent and selective cytotoxicity against cancer cells, significantly reducing their viability. Binding studies confirmed that PNC-27 binds to HDM-2 with an IC50 of approximately 100 nM, mimicking the natural p53-HDM-2 interaction. Furthermore, the peptide induced a 3-fold increase in membrane permeability in cancer cells within 6 hours, indicating selective pore formation, a mechanism not observed in healthy cells. This dual mechanism of action—HDM-2 binding and membrane disruption—appears to be critical for its anti-cancer effects. > PNC-27 treatment resulted in a remarkable 85% reduction in viability for MCF-7 breast cancer cells and 92% for PC-3 prostate cancer cells compared to untreated controls, while showing less than 10% toxicity in normal human fibroblasts.